Comparative Pharmacology
Head-to-head clinical analysis: FOCINVEZ versus MICONAZOLE 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOCINVEZ versus MICONAZOLE 3.
FOCINVEZ vs MICONAZOLE 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOCINVEZ is a small-molecule inhibitor of the interaction between the N-terminal domain of the androgen receptor (AR) and the AR N-terminal domain coactivator binding site, thereby blocking AR-mediated gene transcription and inhibiting prostate cancer cell growth.
Miconazole inhibits fungal cytochrome P450 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability, leakage of cellular contents, and fungal cell death.
Intravenous: 1.5 mg/kg every 6 hours; maximum single dose: 200 mg.
For vaginal candidiasis: 200 mg (one suppository) intravaginally at bedtime for 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; allows twice-daily dosing in most patients, extended in renal impairment (up to 30-40 hours in severe impairment).
Terminal half-life is approximately 24 hours (range 20-30 hours) following topical vaginal application; prolonged in hepatic impairment.
Renal: 70% (unchanged drug), Biliary/Fecal: 20% (metabolites), Other: 10% (minor pathways).
Primarily hepatic metabolism; <1% excreted unchanged in urine; fecal elimination accounts for ~50% of metabolites.
Category C
Category A/B
Antifungal
Antifungal